Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q3 2016 call → NOThe question asks whether management explains the company's business direction by narrating what its counterparties are themselves doing and scaling. I need to check if the transcript shows management speaking about counterparties' growth as the driver of the company's coming activity, with the company already embedded in that growth, and the counterparties' trajectory being early and large relative to the company. Looking at the transcript, management discusses: - Margetuximab Phase 3 SOPHIA trial enrollment - Enoblituzumab trials - MGD009, MGD006, MGD007 trials - MGA012 IND clearance - MGD010 with Takeda (Takeda concluded the agreement, MacroGenics regained rights) - MGD014 with NIAID - MGD013 The discussion of partners like Janssen, Pfizer, Merck, Takeda is mostly about collaborations and clinical trials, not about counterparties' own business expansion driving MacroGenics' growth. The Takeda discussion is about Takeda ending the agreement. The Merck collaboration is about a clinical trial expansion into Asian countries, but this is about trial sites, not about Merck's own business trajectory driving MacroGenics' revenue. Management's forward account is about its own clinical development programs, trial enrollment, and pipeline advancement. There's no substantial narration of counterparties' own growth trajectories (like a customer's store build-out or a partner's product launch) that would drive MacroGenics' coming volume. The collaborations are clinical development partnerships, not supply relationships where the counterparty's expansion drives the company's volume. The answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.